This report contains two small experiments, not one large demonstration that hexarelin never produces response attenuation. Primary report
Study observations
One experiment studied seven older participants during eight days of intranasal exposure; another studied seven older women during fifteen days of oral exposure. GH responsiveness was maintained over those short intervals. IGF-I and IGF-binding-protein findings differed between the experiments, and the abstract reports no observed side effects. Primary report
Our appraisal: do not generalize beyond the tested interval
A short experiment can support a statement about short-term responsiveness. It cannot rule out changes that emerge later. The duration should therefore appear alongside the conclusion whenever this paper is cited in a discussion of desensitization.
Route differences also matter. Different preparations and routes can create different exposure profiles. A comparison between two small experiments should not be treated as a definitive randomized route comparison unless the full design supports that claim.
The absence of reported side effects likewise remains an observation from a small sample. It should not become a universal statement about safety, particularly for long-term use or populations outside the experiment.
Finally, a hormone response in older adults does not establish slowed aging or better function. Those interpretations require directly measured outcomes and appropriate controls. An evidence page should be explicit about this gap rather than relying on the age of participants to imply an anti-aging result.
Before publication, inspect group overlap, allocation, hormone assays, exposure comparability, and completeness of adverse-event collection.
Frequently asked questions
How many experiments were described?
Two, with seven participants in each reported group.
Did they use the same route?
No. One was intranasal and one oral.
Were participants followed for many months?
No. The exposure periods were brief.
Does preserved short-term responsiveness rule out later attenuation?
No. Longer observation is a separate question.
Did the study establish anti-aging benefits?
No. Hormone responses do not establish that claim.
Does no observed side effect prove no risk?
No. Small samples provide limited safety information.
What is the source boundary?
This draft uses the indexed primary abstract, not a completed full-text review.